Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SYN-X develops Alzheimer's screening test

This article was originally published in Clinica

Executive Summary

SYN-X Pharma has introduced a rapid in vitro diagnostic aid that can screen for early signs of Alzheimer's disease from just a few drops of blood. The Nexus Dx assay, intended for use as a point-of-care test in a doctor's or specialist's office, could potentially lead to the initiation of drug treatment, says the Ontario, Canada firm. Drug therapy must begin early in order to slow or minimise the extent of neurological damage associated with the disease. More than 22 million individuals globally will suffer from Alzheimer's disease by 2025, says SYN-X.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT074148

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel